AstraZeneca to buy Belgian cell therapy firm EsoBiotec

AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy
By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of its cell therapy capabilities,
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.
AstraZeneca Makes Potential $1B Cell Therapy Play in EsoBiotec Buy
AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and Gracell Biotechnologies.
AstraZeneca to buy EsoBiotec for up to $1 billion
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
AstraZeneca buys cell therapy biotech in up to $1bn deal
AstraZeneca has struck a deal to acquire biotechnology EsoBiotec for up to $1bn, as the London-listed pharmaceuticals group expands its investments in cell therapies for treating cancer.
AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all outstanding equity of the Belgian biotech for a total consideration of $1 billion—split between an upfront payment of $425 million and up to $575 million in developmental and regulatory milestones.
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent consideration.
AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec
AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company EsoBiotec to advance its cell therapy ambitions.
M&A News: AstraZeneca Seals Belgian Firm EsoBiotec Deal to Boost Cell Therapy
Healthcare giant AstraZeneca (AZN) is set to buy Belgian firm EsoBiotec for up to $1 billion. The deal aims to speed up progress in cell
Fierce Biotech2h
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
AstraZeneca (AZN) Gets a Buy from UBS
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...
The Business Times6h
AstraZeneca to buy EsoBiotec for up to US$1 billion
CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.
Medical Dialogues3h
AstraZeneca to acquire EsoBiotec for up to USD 1 billion
Cambridge: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in ...
AstraZeneca announces Imfinzi approved in European Union
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...
FTSE 100 Live 17 March: AstraZeneca unveils £1bn deal, Qinetiq cuts guidance
Phoenix shares surge on upgraded guidance 08:26 , Graeme Evans The FTSE 100-listed shares of ...